271 related articles for article (PubMed ID: 36121081)
41. Neurological manifestations and pathogenic mechanisms of COVID-19.
Galea M; Agius M; Vassallo N
Neurol Res; 2022 Jul; 44(7):571-582. PubMed ID: 34986754
[TBL] [Abstract][Full Text] [Related]
42. Neurological and neuropsychological adverse effects of SARS-CoV-2 vaccines - where do we stand?
Aliasin MM; Yazdanpanah N; Rezaei N
Rev Neurosci; 2022 Oct; 33(7):721-743. PubMed ID: 35334195
[TBL] [Abstract][Full Text] [Related]
43. The Pandemic of Coronavirus Disease 2019 (COVID-19).
Rashid NN
Curr Mol Med; 2022; 22(9):761-765. PubMed ID: 34789125
[TBL] [Abstract][Full Text] [Related]
44. Effects of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) on the nervous system. What can we expect from SARS -CoV-2?
Monroy-Gómez J; Torres-Fernández O
Biomedica; 2020 Oct; 40(Supl. 2):173-179. PubMed ID: 33152201
[TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms.
Shoraka S; Ferreira MLB; Mohebbi SR; Ghaemi A
Front Immunol; 2021; 12():674922. PubMed ID: 34040615
[TBL] [Abstract][Full Text] [Related]
46. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection.
Moghimi N; Di Napoli M; Biller J; Siegler JE; Shekhar R; McCullough LD; Harkins MS; Hong E; Alaouieh DA; Mansueto G; Divani AA
Curr Neurol Neurosci Rep; 2021 Jun; 21(9):44. PubMed ID: 34181102
[TBL] [Abstract][Full Text] [Related]
47. [SARS-CoV-2 vaccines].
Benfield TL; Helweg-Larsen J
Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
[TBL] [Abstract][Full Text] [Related]
48. SARS-CoV-2 vaccine-related neurological complications.
Oonk NGM; Ettema AR; van Berghem H; de Klerk JJ; van der Vegt JPM; van der Meulen M
Neurol Sci; 2022 Apr; 43(4):2295-2297. PubMed ID: 35050428
[TBL] [Abstract][Full Text] [Related]
49. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222).
Román GC; Gracia F; Torres A; Palacios A; Gracia K; Harris D
Front Immunol; 2021; 12():653786. PubMed ID: 33981305
[TBL] [Abstract][Full Text] [Related]
50. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
Frederiksen LSF; Zhang Y; Foged C; Thakur A
Front Immunol; 2020; 11():1817. PubMed ID: 32793245
[TBL] [Abstract][Full Text] [Related]
51. Proteomic landscape of astrocytes and pericytes infected with HIV/SARS-CoV-2 mono/co-infection, impacting on neurological complications.
Acharya A; Ambikan AT; Thurman M; Malik MR; Dyavar SR; Végvári Á; Neogi U; Byrareddy SN
Res Sq; 2023 Jun; ():. PubMed ID: 37398206
[TBL] [Abstract][Full Text] [Related]
52. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
53. Coagulopathy and Brain Injury Pathogenesis in Post-Covid-19 Syndrome.
Marzoog BA
Cardiovasc Hematol Agents Med Chem; 2022; 20(3):178-188. PubMed ID: 35382728
[TBL] [Abstract][Full Text] [Related]
54. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.
Wiersinga WJ; Rhodes A; Cheng AC; Peacock SJ; Prescott HC
JAMA; 2020 Aug; 324(8):782-793. PubMed ID: 32648899
[TBL] [Abstract][Full Text] [Related]
55. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain.
Li Z; Liu T; Yang N; Han D; Mi X; Li Y; Liu K; Vuylsteke A; Xiang H; Guo X
Front Med; 2020 Oct; 14(5):533-541. PubMed ID: 32367431
[TBL] [Abstract][Full Text] [Related]
56. SARS-CoV-2 infects neurons and induces neuroinflammation in a non-human primate model of COVID-19.
Beckman D; Bonillas A; Diniz GB; Ott S; Roh JW; Elizaldi SR; Schmidt BA; Sammak RL; Van Rompay KKA; Iyer SS; Morrison JH
Cell Rep; 2022 Nov; 41(5):111573. PubMed ID: 36288725
[TBL] [Abstract][Full Text] [Related]
57. Prevalence, pathogenesis and spectrum of neurological symptoms in COVID-19 and post-COVID-19 syndrome: a narrative review.
Wesselingh R
Med J Aust; 2023 Sep; 219(5):230-236. PubMed ID: 37660309
[TBL] [Abstract][Full Text] [Related]
58. Coronavirus Disease 2019 (COVID-19) From the Point of View of Neurologists: Observation of Neurological Findings and Symptoms During the Combat Against a Pandemic.
Özdağ Acarli AN; Samanci B; Ekizoğlu E; Çakar A; Şirin NG; Gündüz T; Parman Y; Baykan B
Noro Psikiyatr Ars; 2020 Jun; 57(2):154-159. PubMed ID: 32550783
[TBL] [Abstract][Full Text] [Related]
59. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
60. The coagulopathy, endotheliopathy, and vasculitis of COVID-19.
Iba T; Connors JM; Levy JH
Inflamm Res; 2020 Dec; 69(12):1181-1189. PubMed ID: 32918567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
